The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis
Abstract
Several preclinical and observational studies have shown that anti-diabetic medications (ADMs) can modify the risk of hepatocellular cancer (HCC) in patients with diabetes mellitus (DM). We performed a systematic review and meta-analyses of studies evaluating the effect of metformin, thiazolidinediones (TZDs), sulfonylureas, and/or insulin on the risk of HCC. We conducted a systematic search of Medline, EMBASE, and Web of Science up to August 2012. Studies were included if they (1) evaluated and clearly defined exposure to metformin, TZDs, sulfonylureas, and/or insulin, (2) reported HCC outcomes in patients with DM, and (3) reported relative risks or odds ratio (OR) or provided data for their estimation. Summary OR estimates with 95% confidence intervals (CIs) were estimated using the random-effects model. Ten studies reporting 22,650 cases of HCC in 334,307 patients with type 2 DM were included in the analysis. Meta-analysis of observational studies showed a 50% reduction in HCC incidence with metformin use (n=8 studies; OR 0.50, 95% CI 0.34-0.73), 62% and 161% increase in HCC incidence with sulfonylurea (n=8 studies; OR 1.62, 95% CI 1.16-2.24) or insulin use (n=7; OR 2.61, 95% CI 1.46-4.65), respectively. TZDs did not modify the risk of HCC (n=4; OR 0.54, 95% CI 0.28-1.02). There was considerable heterogeneity across studies, which was partly explained by study setting, location, and whether the studies adjusted for the concomitant use of other ADMs. Post-hoc analysis of randomized controlled trials did not reveal any significant association between ADM use and risk of HCC. ADMs may modify the risk of HCC in patients with DM, especially in the Western population. However, the effect of each individual agent should be interpreted with caution owing to inherent cancer-modifying effect of the comparator group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
Charlton, M. R., Burns, J. M., Pedersen, R. A., Watt, K. D., Heimbach, J. K., & Dierkhising, R. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.061 · Cited by 1,106
Diabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
El–Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 826
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Randomized Trials or Observational Tribulations?
Pocock, S. J., & Elbourne, D. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422511 · Cited by 550
Welzel, T. M., Graubard, B. I., Zeuzem, S., El-Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 543
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452
Self-citationWang, C., Wang, X., Gong, G., Ben, Q., Qiu, W., Chen, Y., Li, G., & Wang, L. (2012) · International Journal of Cancer · doi:10.1002/ijc.26165 · Cited by 449
Chen, H.-P., Shieh, J.-J., Chang, C.-C., Chen, T.-T., Lin, J.-T., Wu, M.-S., Lin, J.-H., & Wu, C.-Y. (2013) · Gut · doi:10.1136/gutjnl-2011-301708 · Cited by 392
Lee, M.-S., Hsu, C.-C., Wahlqvist, M. L., Tsai, H.-N., Chang, Y.-H., & Huang, Y.-C. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-20 · Cited by 380
Lai, S.-W., Chen, P.-C., Liao, K.-F., Muo, C.-H., Lin, C.-C., & Sung, F.-C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.384 · Cited by 313
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Hassan, M. M., Curley, S. A., Li, D., Kaseb, A., Davila, M., Abdalla, E. K., Javle, M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., et al. (2010) · Cancer · doi:10.1002/cncr.24982 · Cited by 309
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0917 · Cited by 294
Donadon, V., Balbi, M., Mas, M. D., Casarin, P., & Zanette, G. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02223.x · Cited by 292
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 274
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bonanni, B., Puntoni, M., Cazzaniga, M., Pruneri, G., Serrano, D., Guerrieri-Gonzaga, A., Gennari, A., Trabacca, M. S., Galimberti, V., Veronesi, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3769 · Cited by 244
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC
Blandino, G., Valerio, M., Cioce, M., Mori, F., Casadei, L., Pulito, C., Sacconi, A., Biagioni, F., Cortese, G., Galanti, S., et al. (2012) · Nature Communications · doi:10.1038/ncomms1859 · Cited by 242
Zhang, Z.-J., Zheng, Z.-J., Shi, R., Su, Q., Jiang, Q., & Kip, K. E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1267 · Cited by 241
Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives
Ruiter, R., Visser, L. E., van Herk-Sukel, M. P. P., Coebergh, J.-W. W., Haak, H. R., Geelhoed-Duijvestijn, P. H., Straus, S. M. J. M., Herings, R. M. C., & Stricker, B. H. C. (2012) · Diabetes Care · doi:10.2337/dc11-0857 · Cited by 232
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation
Gallagher, E. J., & LeRoith, D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06285.x · Cited by 202
Chang, C.-H., Lin, J.-W., Wu, L.-C., Lai, M.-S., Chuang, L.-M., & Chan, K. A. (2012) · Hepatology · doi:10.1002/hep.25509 · Cited by 193
Yu, M. C., Henderson, B. E., Tong, M. J., & Govindarajan, S. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1820 · Cited by 190
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
for the ADOPT Study Group and the RECORD Steering Committee, Home, P. D., Kahn, S. E., Jones, N. P., Noronha, D., Beck-Nielsen, H., & Viberti, G. (2010) · Diabetologia · doi:10.1007/s00125-010-1804-y · Cited by 177
Impact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
Nkontchou, G., Cosson, E., Aout, M., Mahmoudi, A., Bourcier, V., Charif, I., Ganne-Carrie, N., Grando-Lemaire, V., Vicaut, E., Trinchet, J.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2415 · Cited by 166
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials
Johnson, J. A., & Bowker, S. L. (2010) · Diabetologia · doi:10.1007/s00125-010-1933-3 · Cited by 157
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease
Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S., Perciaccante, A., Valentina, G. D., Gardenal, R., Mas, M. D., Casarin, P., Zanette, G., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2506 · Cited by 144
Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus
Chang, C., Lin, J., Wu, L., Lai, M., & Chuang, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1162 · Cited by 133
Cancer incidence among patients treated with antidiabetic pharmacotherapy
Oliveria, S. A., Koro, C. E., Yood, M. U., & Sowell, M. O. (2008) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.11.002 · Cited by 89
Donadon, V., Balbi, M., Casarin, P., Vario, A., & Alberti, A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5695 · Cited by 80
Kawaguchi, T., Taniguchi, E., Morita, Y., Shirachi, M., Tateishi, I., Nagata, E., & Sata, M. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02191.x · Cited by 78
Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs
Okumura, T. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0310-9 · Cited by 67
Functional role of peroxisome‐proliferator‐activated receptor γ in hepatocellular carcinoma
Wu, C., Farrell, G. C., & Yu, J. Q. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07213.x · Cited by 46
Intensive glucose control and risk of cancer in patients with type 2 diabetes
Stefansdottir, G., Zoungas, S., Chalmers, J. P., Kengne, A. P., Knol, M. J., Leufkens, H. G. M., Patel, A. A., Woodward, M., Grobbee, D. E., & Bruin, M. L. D. (2011) · Diabetologia · doi:10.1007/s00125-011-2104-x · Cited by 41
Statins and Risk Reduction in Hepatocellular Carcinoma: Fact or Fiction?
Singh, P. P., & Singh, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2179 · Cited by 12
Self-citationGlucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations
Johnson, J. A., & Yasui, Y. (2010) · Diabetologia · doi:10.1007/s00125-010-1780-2 · Cited by 9
Cited by
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Epidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Hepatocellular carcinoma: clinical frontiers and perspectives
Bruix, J., Gores, G. J., & Mazzaferro, V. (2014) · Gut · doi:10.1136/gutjnl-2013-306627 · Cited by 1,364
Metadata
- Authors
- Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W.
- Venue
- American Journal of Gastroenterology
- Published
- 2013-06
- Volume
- 108
- Issue
- 6
- Pages
- 881-891
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1980520860
- Cited by
- 320
- References
- 52
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.